戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 estradiol (E2) treatment in a model of human estrogen replacement therapy.
2 beneficial effect may be prevented by use of estrogen replacement therapy.
3 th [(18)F]deuteroaltanserin before and after estrogen replacement therapy.
4 iectomized, and half of the animals received estrogen replacement therapy.
5 t recent hormonal therapy, chemotherapy, and estrogen replacement therapy.
6 cording to current use or duration of use of estrogen replacement therapy.
7 and grain intake, aspirin use and, in women, estrogen replacement therapy.
8 ults differed substantially for women taking estrogen replacement therapy.
9 reased fracture risk that can be reversed by estrogen replacement therapy.
10 17-one (equilin), an equine estrogen used in estrogen replacement therapy.
11 s in rats with OVX that are or are not given estrogen replacement therapy.
12 ng aspirin, antihypertensive medication, and estrogen-replacement therapy.
13 women who were receiving oral or transdermal estrogen-replacement therapy (44 of whom were receiving
14                                              Estrogen replacement therapy after first myocardial infa
15 provides reassurance regarding the safety of estrogen replacement therapy after myocardial infarction
16                                              Estrogen replacement therapy after myocardial infarction
17 isk for reinfarction associated with current estrogen replacement therapy after myocardial infarction
18                             Thus, a model of estrogen replacement therapy, although restoring spine d
19                                              Estrogen replacement therapy and hormonal replacement th
20  attempted to determine the relation between estrogen replacement therapy and the rate of restenosis
21 es evaluating endogenous estrogen levels and estrogen replacement therapy and their relation to the o
22 lity as well as data on age, height, weight, estrogen replacement therapy, and menopause status were
23                                              Estrogen replacement therapy appears to delay the onset
24                                        Since estrogen replacement therapy benefits the outcome of cer
25   These results suggest a mechanism by which estrogen replacement therapy can delay or prevent AD.
26        Epidemiological studies indicate that estrogen replacement therapy decreases the risk of cardi
27                                              Estrogen replacement therapy enhances mood, delays cogni
28                        Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use),
29 ars) were grouped according to HRT received: estrogen replacement therapy (ERT) (n = 13), combined (e
30 logic studies suggest a protective effect of estrogen replacement therapy (ERT) against the developme
31 d with EPRT is substantially higher than for estrogen replacement therapy (ERT) alone.
32 nction in 14 post-menopausal women receiving estrogen replacement therapy (ERT) and 48 post-menopausa
33 ated that women who have used postmenopausal estrogen replacement therapy (ERT) are at reduced risk o
34 ociation between endometrial cancer risk and estrogen replacement therapy (ERT) by CYP17 genotype usi
35   SND, however, has not been recorded during estrogen replacement therapy (ERT) in humans.
36                                              Estrogen replacement therapy (ERT) in postmenopausal wom
37                   Clinical trials have shown estrogen replacement therapy (ERT) is associated with ad
38 nd, therefore, it has been hypothesized that estrogen replacement therapy (ERT) may have a role in pr
39 g-term (2 years) effects of estrogen loss or estrogen replacement therapy (ERT) on cholinergic neuron
40 umerous epidemiological studies suggest that estrogen replacement therapy (ERT) reduces cancer risk i
41  Although observational studies suggest that estrogen replacement therapy (ERT) reduces cardiovascula
42             Clinical studies have shown that estrogen replacement therapy (ERT) reduces the incidence
43                 Some studies have shown that estrogen replacement therapy (ERT) relieves memory impai
44                           The association of estrogen replacement therapy (ERT) with cognitive functi
45 luteal) women, older postmenopausal women on estrogen replacement therapy (ERT), and older postmenopa
46  intake after age 60 y, body weight, current estrogen replacement therapy (ERT), and past oral contra
47                                              Estrogen replacement therapy (ERT), composed of equileni
48 at menarche, parity, oral contraceptive use, estrogen replacement therapy (ERT), or history of oophor
49 on to the duration and the recency of use of estrogen replacement therapy (ERT), simultaneously inclu
50 h 12 postmenopausal women who were not using estrogen replacement therapy (ERT).
51 at 14 months after treatment with placebo or estrogen replacement therapy (ERT).
52    The increased incidence may be delayed by estrogen replacement therapy (ERT).
53 er users as well as by total years of use of estrogen replacement therapy (ERT).
54         We investigated whether the route of estrogen replacement therapy (ET) is the major determina
55 nctional connectivity.SIGNIFICANCE STATEMENT Estrogen replacement therapy following menopause or surg
56                                              Estrogen replacement therapy for 1 year did not slow dis
57 disorders, and provide another rationale for estrogen replacement therapy for postmenopausal women.
58 verse effect and raise concern for long term estrogen replacement therapy for stroke prevention, thes
59  is now strong epidemiological evidence that estrogen replacement therapy has a protective effect in
60                                              Estrogen replacement therapy has also been shown to sign
61 onducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and r
62                                     Although estrogen replacement therapy has been associated with re
63             These findings suggest long-term estrogen replacement therapy has effects on cardiovascul
64      Epidemiologic studies of women who take estrogen replacement therapy, however, consistently repo
65                                      Hormone/estrogen replacement therapy (HRT/ERT) has a positive ef
66             The importance of postmenopausal estrogen replacement therapy in affording protection aga
67               Previously, we have shown that estrogen replacement therapy in postmenopausal women dec
68          Several studies have suggested that estrogen replacement therapy in postmenopausal women imp
69                                              Estrogen replacement therapy in postmenopausal women is
70  raised concern for the protective effect of estrogen replacement therapy in postmenopausal women.
71 ese findings have important implications for estrogen replacement therapy in the context of aging.
72  Ovariectomized Sprague-Dawley rats received estrogen replacement therapy in the form of subcutaneous
73 or binding was significantly increased after estrogen replacement therapy in the right prefrontal cor
74                      One possible outcome of estrogen replacement therapy in vivo could be reduction
75                                     Although estrogen replacement therapy in women has been associate
76                                              Estrogen replacement therapy in women is associated with
77                            Female gender and estrogen-replacement therapy in postmenopausal women are
78                                              Estrogen replacement therapy increases plasma concentrat
79 nd clinical trials consistently suggest that estrogen replacement therapy is associated with benefici
80                    In observational studies, estrogen replacement therapy is associated with decrease
81                                      Because estrogen replacement therapy is known to restore some im
82 t estrogen also has positive effects even if estrogen replacement therapy is not a cure-all.
83  varied significantly with ethnicity, use of estrogen replacement therapy, mammographic breast densit
84 om small clinical trials have suggested that estrogen replacement therapy may be useful for the treat
85 rmed the suggestion from animal studies that estrogen replacement therapy may have an inverse relatio
86    Epidemiologic studies have suggested that estrogen replacement therapy may lower the risk of osteo
87  Recent studies indicate that postmenopausal estrogen replacement therapy may prevent or delay the on
88 tion of Abeta40/42 peptides, suggesting that estrogen replacement therapy may protect women against t
89 ent study do not support the hypothesis that estrogen replacement therapy may slow age-related cognit
90 reast cancer, and that alcohol combined with estrogen replacement therapy may synergistically enhance
91    Observational studies have suggested that estrogen-replacement therapy may reduce a woman's risk o
92 logical data suggest a protective effect for estrogen replacement therapy on colon cancer.
93 e of this study was to assess the effects of estrogen replacement therapy on long-term outcome, inclu
94                               The effects of estrogen replacement therapy on prognosis in women with
95  trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondar
96 enopausal women, whether they were receiving estrogen-replacement therapy or not.
97 ngs that adding progestins to postmenopausal estrogen replacement therapy protects against endometria
98 l epidemiological studies have reported that estrogen replacement therapy protects against the develo
99                                   Short-term estrogen replacement therapy restored trkA mRNA expressi
100                                 In contrast, estrogen replacement therapy significantly increased med
101                                              Estrogen replacement therapy significantly increased med
102  T(4)), and the HPG axis-based treatments of estrogen replacement therapy, the progesterone derivativ
103    This study demonstrates the potential for estrogen replacement therapy to reduce angiographic meas
104 he relation of endogenous estrogen levels or estrogen replacement therapy to the risk of poor cogniti
105  establishing the initiation and duration of estrogen replacement therapy use as a means to prevent c
106 the combination of higher breast density and estrogen replacement therapy use.
107 ed with the combination of dense breasts and estrogen replacement therapy use; there was little diffe
108 for nondense breasts and 74% (180 of 244) in estrogen replacement therapy users and 81% (417 of 513)
109 ommendations in women aged 40-49 years or in estrogen replacement therapy users.
110 available regarding the relative benefits of estrogen replacement therapy versus reductase inhibitors
111  all-cause mortality associated with current estrogen replacement therapy was 0.50 (95% CI 0.25-1.00)
112 s 0.50 (95% CI 0.25-1.00), and that for past estrogen replacement therapy was 0.79 (95% CI 0.56-1.09)
113  interval (CI) 0.32-1.30), and that for past estrogen replacement therapy was 0.90 (95% CI 0.62-1.31)
114                                              Estrogen replacement therapy was associated with an impr

 
Page Top